The results of the ExteNET trial demonstrated that after two years of follow-up, for patients with hormone receptor positive, HER2-positive
early stage breast cancer patients who were treated within one year after the completion of trastuzumab based adjuvant therapy, invasive disease-free survival was 95.3% in the patients treated with neratinib compared with 90.8% in those receiving placebo (hazard ratio = 0.49; 95% CI: (0.30, 0.78); p=0.002).
According to the company, the results of the ExteNET trial demonstrated that after two years of follow-up, for patients with hormone receptor positive, HER2-positive
early stage breast cancer patients who were treated within one year after the completion of trastuzumab based adjuvant therapy, invasive disease-free survival (iDFS) was 95.3% in the patients treated with neratinib compared with 90.8% in those receiving placebo.
"Our results show a quarter of patients with node positive
early stage breast cancer avoided chemotherapy after oncotype testing.
Writing in the British Medical Journal, he said that while the scans were extremely useful in monitoring advanced breast cancer and assessing the response in the breast following chemotherapy, the use of this technology in
early stage breast cancer may do more harm than good.
Of those, 30,000 have only one lymph node involvement."There is currently no question that radiotherapy after mastectomy is effective at decreasing the chances of LRR and is indicated in breast cancer patients with lymph node spread in greater than four nodes and where the risk of LRR is higher than 10 to 15 percent," Kuerer said."However, the need for post-mastectomy radiation in
early stage breast cancer patients has been a topic of great debate within the cancer community for decades," explained Kuerer, the study's senior author.In the 1990s, two landmark randomized trials demonstrated a survival benefit for
early stage breast cancer patients with lymph node metastases who received the therapy post-mastectomy, explained Kuerer.
"This is the first study to find that aspirin can significantly reduce the risk of cancer spread and death for women who have been treated for
early stage breast cancer," said Dr.
Herceptin, the brand name of trastuzumab, has been licensed by the National Institute for Clinical Excellence to be given to women with
early stage breast cancer.
This study is the first large-scale trial to demonstrate the significant antitumor benefit of Zometa and the findings may allow oncologists to further improve the standard of care for premenopausal women with hormone-sensitive
early stage breast cancer.- TradeArabia News Service
Major Independent Trial Demonstrates Anticancer Benefit of Zometa (Zoledronic Acid) in Women With
Early Stage Breast Cancer;
Clatterbridge Centre for Oncology is the first cancer centre in the UK to offer a brachytherapy treatment known as Mam-moSite for patients with
early stage breast cancer.
Researchers concluded that among survivors of
early stage breast cancer, adoption of a diet very high in vegetables, fruit, and fiber and low in fat did not reduce additional breast cancer events or mortality during a 7-year follow-up period.
Benefits of supervised group exercise programme for women being treated for
early stage breast cancer: pragmatic randomised controlled trial.